erlotinib hydrochloride has been researched along with kaempferol in 1 studies
Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (kaempferol) | Trials (kaempferol) | Recent Studies (post-2010) (kaempferol) |
---|---|---|---|---|---|
4,353 | 786 | 3,033 | 1,577 | 6 | 900 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, F; Chen, M; Guo, Y; Liu, B; Shen, C; Zhang, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and kaempferol
Article | Year |
---|---|
Kaempferol potentiates the sensitivity of pancreatic cancer cells to erlotinib via inhibition of the PI3K/AKT signaling pathway and epidermal growth factor receptor.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaempferols; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Docking Simulation; Network Pharmacology; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |